Central serous chorioretinopathy: an evidence-based treatment guideline
Central serous chorioretinopathy: an evidence-based treatment guideline
Central serous chorioretinopathy (CSC) is a relatively common disease that causes vision loss due to macular subretinal fluid leakage and it is often associated with reduced vision-related quality of life. In CSC, the leakage of subretinal fluid through defects in the retinal pigment epithelial layer's outer blood-retina barrier appears to occur secondary to choroidal abnormalities and dysfunction. The treatment of CSC is currently the subject of controversy, although recent data obtained from several large randomized controlled trials provide a wealth of new information that can be used to establish a treatment algorithm. Here, we provide a comprehensive overview of our current understanding regarding the pathogenesis of CSC, current therapeutic strategies, and an evidence-based treatment guideline for CSC. In acute CSC, treatment can often be deferred for up to 3–4 months after diagnosis; however, early treatment with either half-dose or half-fluence photodynamic therapy (PDT) with the photosensitive dye verteporfin may be beneficial in selected cases. In chronic CSC, half-dose or half-fluence PDT, which targets the abnormal choroid, should be considered the preferred treatment. If PDT is unavailable, chronic CSC with focal, non-central leakage on angiography may be treated using conventional laser photocoagulation. CSC with concurrent macular neovascularization should be treated with half-dose/half-fluence PDT and/or intravitreal injections of an anti-vascular endothelial growth factor compound. Given the current shortage of verteporfin and the paucity of evidence supporting the efficacy of other treatment options, future studies—ideally, well-designed randomized controlled trials—are needed in order to evaluate new treatment options for CSC.
Central serous chorioretinopathy, Micropulse laser, Mineralocorticoid receptor antagonist, Photodynamic therapy, Treatment guideline
Feenstra, Helena
215a241a-169f-4931-a911-5294547f7bf4
Van Dijk, Elon H.C.
329df4dd-691a-4218-ba65-dcb884bb597a
Cheung, Chui Ming Gemmy
5ea55fb6-2341-44b2-ae58-be2393c9b097
Lotery, Andrew
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
July 2024
Feenstra, Helena
215a241a-169f-4931-a911-5294547f7bf4
Van Dijk, Elon H.C.
329df4dd-691a-4218-ba65-dcb884bb597a
Cheung, Chui Ming Gemmy
5ea55fb6-2341-44b2-ae58-be2393c9b097
Lotery, Andrew
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Feenstra, Helena, Van Dijk, Elon H.C. and Cheung, Chui Ming Gemmy
,
et al.
(2024)
Central serous chorioretinopathy: an evidence-based treatment guideline.
Progress in Retinal and Eye Research, 101, [101236].
(doi:10.1016/j.preteyeres.2024.101236).
Abstract
Central serous chorioretinopathy (CSC) is a relatively common disease that causes vision loss due to macular subretinal fluid leakage and it is often associated with reduced vision-related quality of life. In CSC, the leakage of subretinal fluid through defects in the retinal pigment epithelial layer's outer blood-retina barrier appears to occur secondary to choroidal abnormalities and dysfunction. The treatment of CSC is currently the subject of controversy, although recent data obtained from several large randomized controlled trials provide a wealth of new information that can be used to establish a treatment algorithm. Here, we provide a comprehensive overview of our current understanding regarding the pathogenesis of CSC, current therapeutic strategies, and an evidence-based treatment guideline for CSC. In acute CSC, treatment can often be deferred for up to 3–4 months after diagnosis; however, early treatment with either half-dose or half-fluence photodynamic therapy (PDT) with the photosensitive dye verteporfin may be beneficial in selected cases. In chronic CSC, half-dose or half-fluence PDT, which targets the abnormal choroid, should be considered the preferred treatment. If PDT is unavailable, chronic CSC with focal, non-central leakage on angiography may be treated using conventional laser photocoagulation. CSC with concurrent macular neovascularization should be treated with half-dose/half-fluence PDT and/or intravitreal injections of an anti-vascular endothelial growth factor compound. Given the current shortage of verteporfin and the paucity of evidence supporting the efficacy of other treatment options, future studies—ideally, well-designed randomized controlled trials—are needed in order to evaluate new treatment options for CSC.
Text
CSC_an_evidence_based_treatment_guideline_clean_copy
- Accepted Manuscript
Text
1-s2.0-S1350946224000016-main
- Proof
More information
Accepted/In Press date: 2 January 2024
e-pub ahead of print date: 1 February 2024
Published date: July 2024
Additional Information:
Publisher Copyright:
© 2024 The Authors
Keywords:
Central serous chorioretinopathy, Micropulse laser, Mineralocorticoid receptor antagonist, Photodynamic therapy, Treatment guideline
Identifiers
Local EPrints ID: 486883
URI: http://eprints.soton.ac.uk/id/eprint/486883
ISSN: 1350-9462
PURE UUID: 7c2fa1ce-e247-4e39-a296-195d39ab30b7
Catalogue record
Date deposited: 08 Feb 2024 17:32
Last modified: 12 Jul 2024 01:41
Export record
Altmetrics
Contributors
Author:
Helena Feenstra
Author:
Elon H.C. Van Dijk
Author:
Chui Ming Gemmy Cheung
Corporate Author: et al.
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics